HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Manley HJ, Majchrzak KM, Sanders R, et al.

Screening for SARS-CoV-2 (COVID) Infection in Chronic Dialysis Patients: A Nonprofit Provider's Experience

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:32A 2020


The CDC recommends screening of all patients for COVID exposure history and or signs and symptoms prior to treatment. In order to limit the spread of COVID within our facilities, Dialysis Clinic Inc. screens all patients prior their in-center hemodialysis treatment or peritoneal dialysis visit consistent with recommendations.


We describe the outpatient screening results of our dialysis patients having a positive screen as patients under investigation (PUI) to activate local protocols for isolation and testing. We determined the frequencies of positive screening parameters and rate of identifying COVID patients.


From 2/17 to 5/1, 2020, facilities screened 15,602 patients over 402,002 in-person visits, identifying 959 PUI’s (6%). Among PUIs, 61 of 351 (17%) COVID+ patients were correctly triaged prior to COVID+ diagnosis. In the subset of 788 PUIs screened prior to 4/11/20 where we were able to catalogue reasons for positive screening, 149 (19%) had exposure only and 639 exhibited symptoms (81%), of which 15 had exposure; 34 resided in group home (GH) and 7 had both exposure and GH residence. It was determined 41 (6.4%) were COVID+. Frequency of symptoms elicited by PUI are shown below.


959 PUIs were identified and isolated by our screening process, resulting in the successful preemptive triage of 61 COVID+ (6%) patients before testing positive, potentially limiting infection spread in the facility. Cough and fever were the most common reasons for positive screen, and fever was most commonly associated with COVID+ diagnosis. However, the majority (83%) of COVID+ patients were primarily asymptomatic and hence not captured by screening.

COVID-related SymptomCOVID+
Cough11 (27%)320 (54%)331 (52%)
Fever (≥100 F)30 (73%)153 (26%)183 (29%)
Shortness of Breaths8 (20%)132 (22%)140 (22%)
Sore Throat1 (2%)138 (23%)139 (22%)
02 Saturation ≤90%6 (15%)60 (10%)66 (10%)
Other Symptom2 (5%)43 (7%)45 (7%)
Chills3 (7%)24 (4%)27 (4%)
Diarrhea5 (12%)16 (3%)21 (3%)
Headache1 (2%)13 (2%)14 (2%)
Vomiting2 (5%)7 (1%)9 (1%)
Abdominal pain0 (0%)3 (1%)3 (0%)

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.